Sutro Biopharma (SUTRO) Prices $110M Underwritten Offering as Shares Surge 18%

Sutro Biopharma (SUTRO) priced an underwritten public offering of 10 million shares at $11 per share, raising $110 million. The offering closed February 10, 2026, following strong investor demand. The stock closed at $44.18, up 18% on the NASDAQ, reflecting heightened interest in the company's RNA-based therapies and pipeline advancements.